Mukul Verma 2/17/22 Mukul Verma 2/17/22 KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers Read More Mukul Verma 5/26/21 Mukul Verma 5/26/21 KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers-- Read More
Mukul Verma 2/17/22 Mukul Verma 2/17/22 KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers Read More
Mukul Verma 5/26/21 Mukul Verma 5/26/21 KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers-- Read More
